CN108601787B - 用于治疗恶性肿瘤的组合疗法 - Google Patents

用于治疗恶性肿瘤的组合疗法 Download PDF

Info

Publication number
CN108601787B
CN108601787B CN201680072973.3A CN201680072973A CN108601787B CN 108601787 B CN108601787 B CN 108601787B CN 201680072973 A CN201680072973 A CN 201680072973A CN 108601787 B CN108601787 B CN 108601787B
Authority
CN
China
Prior art keywords
compound
azacitidine
day
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680072973.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN108601787A (zh
Inventor
维韦克·萨罗杰·库马尔·乔普拉
乔治·德马蒂诺
劳里·A·肯文
罗伯特·道格拉斯·奈特
凯尔·麦克白
克里希南·维斯瓦纳汉
许强
塞缪尔·V·阿格雷斯塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Celgene Corp
Original Assignee
Celgene Corp
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Agios Pharmaceuticals Inc filed Critical Celgene Corp
Publication of CN108601787A publication Critical patent/CN108601787A/zh
Application granted granted Critical
Publication of CN108601787B publication Critical patent/CN108601787B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680072973.3A 2015-10-15 2016-10-14 用于治疗恶性肿瘤的组合疗法 Active CN108601787B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562242218P 2015-10-15 2015-10-15
US62/242,218 2015-10-15
PCT/US2016/057102 WO2017066611A1 (en) 2015-10-15 2016-10-14 Combination therapy for treating malignancies

Publications (2)

Publication Number Publication Date
CN108601787A CN108601787A (zh) 2018-09-28
CN108601787B true CN108601787B (zh) 2022-07-29

Family

ID=57219007

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680072973.3A Active CN108601787B (zh) 2015-10-15 2016-10-14 用于治疗恶性肿瘤的组合疗法

Country Status (16)

Country Link
US (2) US10695352B2 (OSRAM)
EP (1) EP3362070B1 (OSRAM)
JP (1) JP6895956B2 (OSRAM)
KR (1) KR102701893B1 (OSRAM)
CN (1) CN108601787B (OSRAM)
AU (1) AU2016340098B2 (OSRAM)
BR (1) BR112018007447B1 (OSRAM)
CA (1) CA3002029A1 (OSRAM)
CL (1) CL2018000955A1 (OSRAM)
EA (1) EA036129B1 (OSRAM)
ES (1) ES2862730T3 (OSRAM)
IL (1) IL258580B (OSRAM)
MX (1) MX381582B (OSRAM)
SG (2) SG10201912869WA (OSRAM)
WO (1) WO2017066611A1 (OSRAM)
ZA (1) ZA201802420B (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9986928B2 (en) 2013-12-09 2018-06-05 Medtronic, Inc. Noninvasive cardiac therapy evaluation
EA036325B1 (ru) 2014-03-14 2020-10-27 Аджиос Фармасьютикалз, Инк. Фармацевтическая композиция на основе твердой дисперсии ингибитора idh1
ES2897959T3 (es) * 2015-10-15 2022-03-03 Servier Lab Terapia de combinación para tratar neoplasias malignas
IL311873A (en) 2015-10-15 2024-06-01 Agios Pharmaceuticals Inc Combination therapy for treating malignancies
UA123401C2 (uk) 2015-10-15 2021-03-31 Аджиос Фармасьютікалз, Інк. Комбінована терапія для лікування злоякісних пухлин
US11219769B2 (en) 2016-02-26 2022-01-11 Medtronic, Inc. Noninvasive methods and systems of determining the extent of tissue capture from cardiac pacing
BR112019004356A2 (pt) 2016-09-07 2019-05-28 Celgene Corporation composições de comprimido
EP3618828B1 (en) 2017-05-05 2023-11-01 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
CN119280245A (zh) * 2017-06-12 2025-01-10 法国施维雅药厂 使用组合疗法治疗脑肿瘤的方法
CN110869029A (zh) * 2017-07-09 2020-03-06 拜欧赛特有限公司 组合癌症治疗
CN111902082B (zh) 2018-03-29 2025-03-07 美敦力公司 左心室辅助设备调整和评估
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
US20220017489A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Solid dispersions for treatment of cancer
US20220017490A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
US12215094B2 (en) 2018-11-02 2025-02-04 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
US11697025B2 (en) 2019-03-29 2023-07-11 Medtronic, Inc. Cardiac conduction system capture
US11701428B2 (en) * 2019-04-29 2023-07-18 Immunogen, Inc. Therapeutic combinations comprising anti-CD123 immunoconjugates
BR112021025537A2 (pt) 2019-06-20 2022-03-03 Celgene Quanticel Res Inc Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica
US11497431B2 (en) 2019-10-09 2022-11-15 Medtronic, Inc. Systems and methods for configuring cardiac therapy
US12201843B2 (en) 2019-10-09 2025-01-21 Medtronic, Inc. Synchronizing external electrical activity
EP4058028B1 (en) 2019-11-14 2025-03-05 Celgene Corporation Pediatric formulations for treatment of cancer
CN111087408B (zh) * 2020-01-03 2021-04-02 浙江大学 一种大环结构的idh2突变体抑制剂及其医药用途
WO2022192621A1 (en) * 2021-03-12 2022-09-15 Celgene Corporation Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
WO2015006592A1 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015017821A2 (en) * 2013-08-02 2015-02-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT998271E (pt) 1997-06-06 2005-10-31 Depomed Inc Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
PT1251832E (pt) 2000-02-04 2007-01-31 Depomed Inc Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
AU2009246926B2 (en) * 2008-05-15 2014-06-26 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
EP2307002B1 (en) * 2008-06-09 2013-01-02 Cyclacel Limited Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine
CN108524505A (zh) 2009-03-13 2018-09-14 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
ES2812537T3 (es) 2009-10-21 2021-03-17 Agios Pharmaceuticals Inc Métodos y composiciones para trastornos relacionados con la proliferación celular
MY176125A (en) * 2011-11-03 2020-07-24 Takeda Pharmaceuticals Co Administration of nedd8-activating enzyme inhibitor and hypomethylating agent
ES2675760T3 (es) 2012-01-06 2018-07-12 Agios Pharmaceuticals, Inc. Compuestos terapéuticamente activos y métodos de uso de los mismos
WO2015018060A1 (en) 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
JP2017529382A (ja) 2014-09-29 2017-10-05 アギオス ファーマシューティカルス，インコーポレーテッド 治療活性を有する化合物及びその使用方法
KR102628370B1 (ko) 2015-02-04 2024-01-24 르 라보레또레 쎄르비에르 치료적 활성 화합물 및 이들의 사용 방법
US9751863B2 (en) 2015-08-05 2017-09-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
IL311873A (en) 2015-10-15 2024-06-01 Agios Pharmaceuticals Inc Combination therapy for treating malignancies
IL299563A (en) 2015-12-04 2023-02-01 Agios Pharmaceuticals Inc Methods of treatment of acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras
CA3015753A1 (en) 2016-02-26 2017-08-31 Celgene Corporation Idh2 inhibitors for the treatment of haematological maligancies and solid tumours

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
WO2015006592A1 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015017821A2 (en) * 2013-08-02 2015-02-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
SG11201802964QA (en) 2018-05-30
KR102701893B1 (ko) 2024-09-03
EP3362070A1 (en) 2018-08-22
JP6895956B2 (ja) 2021-06-30
EP3362070B1 (en) 2021-01-27
US10695352B2 (en) 2020-06-30
US20180303840A1 (en) 2018-10-25
ES2862730T3 (es) 2021-10-07
WO2017066611A1 (en) 2017-04-20
MX381582B (es) 2025-03-12
US20210100805A1 (en) 2021-04-08
EA036129B1 (ru) 2020-10-01
BR112018007447A2 (en) 2018-10-23
JP2018535951A (ja) 2018-12-06
ZA201802420B (en) 2020-08-26
AU2016340098A1 (en) 2018-05-10
CL2018000955A1 (es) 2018-09-14
EA201890961A1 (ru) 2018-11-30
CN108601787A (zh) 2018-09-28
MX2018004599A (es) 2018-09-21
SG10201912869WA (en) 2020-02-27
BR112018007447B1 (pt) 2023-12-05
IL258580A (en) 2018-05-31
KR20180064529A (ko) 2018-06-14
NZ741433A (en) 2024-07-26
IL258580B (en) 2021-05-31
CA3002029A1 (en) 2017-04-20
AU2016340098B2 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
CN108601787B (zh) 用于治疗恶性肿瘤的组合疗法
CN108697698B (zh) 用于治疗恶性肿瘤的组合疗法
EP3383400B1 (en) Methods of treatment of malignancies
EP3419593B1 (en) Enasidenib for use in the treatment of relapsed or refractory acute myeloid leukaemia
EP3493809B1 (en) Enasidenib for treatment of myelodysplastic syndrome
HK1259245B (en) Combination therapy for treating malignancies
HK1259245A1 (en) Combination therapy for treating malignancies
JP2019528260A (ja) 骨髄異形成症候群の治療方法
BR122024000250B1 (pt) Uso de um inibidor de desidrogenase isocitrato1 (IDH1) mutante e um agente desmetilante
BR112018007656B1 (pt) Uso do inibidor de isocitrato desidrogenase 1 mutante (IDH1) e azacitidina
BR122024020713A2 (pt) Uso de composto em terapia de combinação para tratamento de doenças malignas

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20221223

Address after: new jersey

Patentee after: CELGENE Corp.

Patentee after: LES LABORATOIRES SERVIER

Address before: new jersey

Patentee before: CELGENE Corp.

Patentee before: AGIOS PHARMACEUTICALS, Inc.

TR01 Transfer of patent right